A Study of Evacetrapib and Digoxin in Healthy Participants

Completed · Phase 1

Conditions studied: Healthy Volunteers

In brief

The main purpose of this study is to determine how much digoxin gets into the blood stream and how long it takes the body to get rid of it when given with the study drug evacetrapib. This study will also look at the effect of evacetrapib on the removal of digoxin from the body by the kidneys. Information about any side effects that may occur will be collected. This study will last approximately 33 days for each participant, not including screening.

Key facts

Study ID

NCT01897493

Run by

Eli Lilly and Company

People needed

16

Starts

2013-07-01

Expected to finish

2013-09-01

Last updated by the study team

2018-10-09

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Overtly healthy males and females (of non-childbearing potential)
• Have a body mass index of 18 to 32 kilograms per square meter (kg/m\^2)
• Normal renal function

You may not qualify if…

• Participants who currently smoke or use tobacco or nicotine products

Where it is running

• For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. — Dallas, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.